News

NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST.

Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV vaccine with the potential to prevent HIV infection and treat HIV. The effectiveness of the new vaccine results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is seeking a collaboration partner for the NCI Phase 2 and 3 clinical trials for this vaccine and/or a licensing partner to bring the vaccine to market. Dr. Franchini will also discuss two other NCI technologies that further enhance the vaccine’s effectiveness:

• Improved HIV Vaccines Through Ras Activation
• Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination

Why Attend?
• Assess co-developing and/or licensing this technology
• Interact with the inventor, ask questions and provide feedback
• Learn how to partner with the NCI

Who should attend?
• Business development professionals
• Drug development professionals
• Biotech/pharma/academia researchers
• Investors and entrepreneurs

About the vaccine:
This new vaccine’s effectiveness in macaques results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is planning a Phase 1 clinical study on this vaccine at the NIH Clinical Center in late 2022.

What an HIV Vaccine could mean for patients – potential new standard of care:
Since 1985, the FDA approved 57 HIV therapeutics in seven HIV drug classes. The current standard of care for treating HIV infection is a daily oral treatment with antiretroviral therapeutics, which are often combined with three other HIV medications selected from at least two different HIV drug classes.

An HIV vaccine would completely change the current way HIV infections are addressed. For uninfected individuals, the HIV vaccine would protect them from contracting the disease. For infected individuals, it would substantially improve their quality of life by:
• Providing a potential cure, rather than treating symptoms
• Eliminating the virus, rather than suppressing it
• Providing a prime/boost treatment regimen for a finite amount of time, rather than lifelong daily dosing

Visit the link here for additional information and to register.

Recent News

03/23/2023

Children’s National Hospital names Michelle Riley-Brown as new CEO to succeed Kurt Newman

The Children’s National Board of Directors announced that Michelle Riley-Brown, MHA, FACHE, has been named as the new president and chief executive officer (CEO) of Children’s National Hospital. On July 1, Riley-Brown will succeed Kurt Newman, M.D. , who is retiring after 11 years as president and CEO. Riley-Brown is an accomplished executive with over

03/21/2023

Mason leads planning study to position Northern Virginia as a premier location for the life science industry

During the past several years, industry demand for a skilled life science workforce has been surging. In Virginia, while there are currently shortages in almost all health-related professions, little is known about whether there is an adequate supply of life science workers to meet the needs of employers. Now George Mason University is working toward

03/21/2023

California invests $50M to partner with Civica Rx on insulin manufacturing

California Gov. Gavin Newsom has announced a new contract with nonprofit drugmaker Civica Rx, a move that brings the state one step closer to creating its own line of insulin to bring down the cost of the drug. Once the medicines are approved by the Food and Drug Administration, Newsom said at a press conference